In this issue of JAMA, Thamer and colleagues1 examine the use of epoetin in US dialysis facilities. This report comes at an opportune time given the recent US Food and Drug Administration (FDA) advisory warning that epoetin and darbepoetin (erythropoiesis-stimulating agents [ESAs]) result in “an increased number of deaths and of non-fatal heart attacks, strokes, heart failure, and blood clots when ESAs were adjusted to maintain . . . hemoglobin more than 12 g/dL.”2 The FDA recommends using just enough ESA to maintain the lowest hemoglobin level necessary to avoid the need for transfusions and ensure hemoglobin level does not exceed 12 g/dL.2 The data from Thamer and colleagues1 suggest higher epoetin use was the goal, and targeting higher hemoglobin levels was the means to that goal.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 25
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Care at the Close of Life EDUCATION GUIDESPractical Considerations in Dialysis Withdrawal
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.